Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma

Journal of Clinical Oncology

Volumn 27, Issue 5, 2009, Pages 791-798

  Chakraborty, Sujata ^a   Sun, Can Lan ^a   Francisco, Liton ^a   Sabado, Melanie ^a   Li, Ang ^a   Chang, Karen L ^a   Forman, Stephen ^a   Bhatia, Smita ^a   Bhatia, Ravi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOTRANSPLANTATION; BLOOD SAMPLING; CASE CONTROL STUDY; CELL REGENERATION; CHROMOSOME LOSS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMATOPOIETIC STEM CELL; HIGH RISK POPULATION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TELOMERE;

BLOTTING, SOUTHERN; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LONGITUDINAL STUDIES; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; TELOMERE; TRANSPLANTATION, AUTOLOGOUS;

EID: 59949101341     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.1033     Document Type: Article

References (64)

1. Boivin JF, Hutchison GB, Zauber AG, et al: Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 87:732-741, 1995
2. Meadows AT, Obringer AC, Marrero O, et al: Second malignant neoplasms following childhood Hodgkin's disease: Treatment and splenectomy as risk factors. Med Pediatr Oncol 17:477-484, 1989
3. Pedersen-Bjergaard J, Larsen SO: Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 307:965-971, 1982
4. van Leeuwen FE, Chorus AM, van den Belt- Dusebout AW, et al: Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063-1073, 1994
5. Valagussa P, Santoro A, Fossati-Bellani F, et al: Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4:830-837, 1986
6. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1988
7. Cimino G, Papa G, Tura S, et al: Second primary cancer following Hodgkin's disease: Updated results of an Italian multicentric study. J Clin Oncol 9:432-437, 1991
8. Andrieu JM, Ifrah N, Payen C, et al: Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 8:1148-1154, 1990
9. Kaldor JM, Day NE, Pettersson F, et al: Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322:1-6, 1990
10. Sankila R, Garwicz S, Olsen JH, et al: Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study in the five Nordic countries-Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 14:1442-1446, 1996
11. Lavey RS, Eby NL, Prosnitz LR: Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 66:80-88, 1990
12. Travis LB, Curtis RE, Glimelius B, et al: Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 85: 1932-1937, 1993
13. Curtis RE, Boice JD Jr, Stovall M, et al: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-1751, 1992
14. Bhatia S, Ramsay NKC, Steinbuch M, et al: Malignant neoplasms following bone marrow transplantation. Blood 87:3633-3639, 1996
15. Traweek ST, Slovak ML, Nademanee AP, et al: Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 84:957-963, 1994
16. Stone RM, Neuberg D, Soiffer R, et al: Myelo- dysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535-2542, 1994
17. Miller JS, Arthur DC, Litz CE, et al: Myelodys- plastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 83:3780-3786, 1994
18. Krishnan A, Bhatia S, Slovak ML, et al: Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 95:1588-1593, 2000
19. Darrington DL, Vose JM, Anderson JR, et al: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534, 1994
20. Andre M, Henry-Amar M, Blaise D, et al: Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 92:1933-1940, 1998
21. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al: Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT- EBMT Lymphoma and Late Effects Working Parties; European Group for Blood and Marrow Transplantation. Br J Haematol 106:1020-1026, 1999
22. Wheeler C, Khurshid A, Ibrahim J, et al: Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autolo- gous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma 40: 499-509, 2001
23. Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 17: 3128-3135, 1999
24. Harrison CN, Gregory W, Hudson GV, et al: High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer 81:476-483, 1999
25. Kalaycio M, Rybicki L, Pohlman B, et al: Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 24:3604-3610, 2006
26. Govindarajan R, Jagannath S, Flick JT, et al: Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 95:349-353, 1996
27. Brummendorf TH, Balabanov S: Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia 20:1706-1716, 2006
28. Feldser DM, Greider CW: Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11:461-469, 2007
29. Blackburn EH, Greider CW, Szostak JW: Telomeres and telomerase: The path from maize, Tetra- hymena and yeast to human cancer and aging. Nat Med 12:1133-1138, 2006
30. de Pauw ES, Otto SA, Wijnen JT, et al: Long-term follow-up of recipients of allogeneic bone marrow grafts reveals no progressive telomere shortening and provides no evidence for haematopoietic stem cell exhaustion. Br J Haematol 116: 491-496, 2002
31. Brummendorf TH, Rufer N, Baerlocher GM, et al: Limited telomere shortening in hematopoietic stem cells after transplantation. Ann N Y Acad Sci 938:1-7, 2001
32. Seligman SJ: Telomere shortening in recipients of bone-marrow transplants. Lancet 351:1287-1288, 1998
33. Wynn RF, Cross MA, Hatton C, et al: Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 351: 178-181, 1998
34. Shay JW: Accelerated telomere shortening in bone-marrow recipients. Lancet 351:153-154, 1998
35. Lee JJ, Nam CE, Cho SH, et al: Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy. Ann Hematol 82: 492-495, 2003
36. Unryn BM, Hao D, Gluck S, et al: Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res 12:6345-6350, 2006
37. Counter CM, Gupta J, Harley CB, et al: Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85:2315-2320, 1995
38. Ohyashiki JH, Iwama H, Yahata N, et al: Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 5:1155-1160, 1999
39. Ohyashiki K, Iwama H, Yahata N, et al: Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk Lymphoma 42:291-299, 2001
40. Terasaki Y, Okumura H, Ohtake S, et al: Accelerated telomere length shortening in granulo- cytes: A diagnostic marker for myeloproliferative diseases. Exp Hematol 30:1399-1404, 2002
41. Ly H, Calado RT, Allard P, et al: Functional characterization of telomerase RNA variants found in patients with hematologic disorders. Blood 105: 2332-2339, 2005
42. Savage SA, Calado RT, Xin ZT, et al: Genetic variation in telomeric repeat binding factors 1 and 2 in aplastic anemia. Exp Hematol 34:664-671, 2006
43. Takeuchi J, Ly H, Yamaguchi H, et al: Identification and functional characterization of novel telomerase variant alleles in Japanese patients with bone-marrow failure syndromes. Blood Cells Mol Dis 40:185-191, 2008
44. Yamaguchi H, Calado RT, Ly H, et al: Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352:1413-1424, 2005
45. Mason PJ: Stem cells, telomerase and dyskeratosis congenita. Bioessays 25:126-133, 2003
46. Bhatia R, Van Heijzen K, Palmer A, et al: Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol 23:6699-6711, 2005
47. Larsson I, Lundgren E, Nilsson K, et al: A human neoplastic hematopoietic cell line producing a fibroblast type of interferon. Dev Biol Stand 42: 193-197, 1979
48. Hultdin M, Gronlund E, Norrback K, et al: Telomere analysis by fluorescence in situ hybridization and flow cytometry. Nucleic Acids Res 26:3651-3656, 1998
49. Roos G, Hultdin M: Flow cytometric determination of telomere length. Cytometry 45:79-80, 2001
50. Law HKW, Lau YL: DNA index and Q Flow FISH measurement of telomere length. Cytometry 45:80, 2001
51. Schmid I, Dagarag MD, Hausner MA, et al: Simultaneous flow cytometric analysis of two cell surface markers, telomere length, and DNA content. Cytometry 49:96-105, 2002
52. Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345:458-460, 1990
53. Wege H, Chui MS, Le HT, et al: SYBR green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res 31:E3-3, 2003
54. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
55. Akiyama M, Hoshi Y, Sakurai S, et al: Changes of telomere length in children after hematopoietic stem cell transplantation. Bone Marrow Transplant 21:167-171, 1998
56. Widmann T, Kneer H, Konig J, et al: Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation. Exp Hematol 36:104-110, 2008
57. Rocci A, Ricca I, Dellacasa C, et al: Long-term lymphoma survivors following high-dose chemotherapy and autograft: Evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hemato- poietic stem cell reservoir. Exp Hematol 35:673-681, 2007
58. Vulliamy TJ, Knight SW, Mason PJ, et al: Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita. Blood Cells Mol Dis 27:353-357, 2001
59. Campisi J: Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120:513-522, 2005
60. De Lange T: Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol 70:197-204, 2005
61. Feldser DM, Hackett JA, Greider CW: Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer 3:623-627, 2003
62. Lansdorp PM: Telomeres, stem cells, and hematology. Blood 111:1759-1766, 2008
63. Ball SE, Gibson FM, Rizzo S, et al: Progressive telomere shortening in aplastic anemia. Blood 91: 3582-3592, 1998
64. Calado RT, Young NS: Telomere maintenance and human bone marrow failure. Blood 111:4446-4455, 2008